Chugai Wins Approval for New Evrysdi Tablet, Offering Greater Convenience for SMA Patients

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has received approval from Japan’s Ministry of Health, Labour and Welfare for its latest formulation of Evrysdi® (risdiplam) in a 5mg tablet form. As the only oral treatment for spinal muscular atrophy (SMA), Evrysdi has been widely used in its liquid dry syrup form. However, the newly approved tablet aims to simplify the medication process for patients aged 2 and older who weigh at least 20 kg. Unlike the dry syrup, which requires refrigeration and precise measuring, the tablet can be stored at room temperature, making it easier to transport and administer.

Dr. Osamu Okuda, President and CEO of Chugai, expressed enthusiasm for this advancement, emphasizing how the new formulation enhances convenience for patients and caregivers. By offering an alternative that aligns with different lifestyles, Chugai hopes to improve treatment accessibility and comfort. The approval is based on a bioequivalence study conducted by Roche, confirming that the tablet delivers the same efficacy and safety as the liquid formulation. As Chugai continues its partnership with Roche, the SMA Foundation, and PTC Therapeutics, this new development marks a significant step toward improving daily life for individuals with SMA.